Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment (2013 - 2016)

Amphastar Pharmaceuticals' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $114000.0 for Q2 2016.

• In Q2 2016, Asset Writedowns and Impairment changed N/A year-over-year to $114000.0; the TTM figure through Dec 2023 stood at $114000.0 (changed N/A YoY), while the FY2023 annual figure was $2.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment was $114000.0 for Q2 2016 at Amphastar Pharmaceuticals, down from $217000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $217000.0 in Q1 2016 to a low of $4000.0 in Q3 2015.
• Historically, Asset Writedowns and Impairment has averaged $113555.6 across 4 years, with a median of $120000.0 in 2013.
• Biggest YoY gain for Asset Writedowns and Impairment was 64.1% in 2015; the steepest drop was 69.23% in 2015.
• A 4-year view of Asset Writedowns and Impairment shows it stood at $120000.0 in 2013, then sank by 35.0% to $78000.0 in 2014, then soared by 64.1% to $128000.0 in 2015, then declined by 10.94% to $114000.0 in 2016.
• The last three Asset Writedowns and Impairment figures came in at $114000.0 (Q2 2016), $217000.0 (Q1 2016), and $128000.0 (Q4 2015), per Business Quant data.